Your browser doesn't support javascript.
loading
LCL161 enhances expansion and survival of engineered anti-tumor T cells but is restricted by death signaling.
Afsahi, Arya; Silvestri, Christopher M; Moore, Allyson E; Graham, Carly F; Bacchiochi, Kaylyn; St-Jean, Martine; Baker, Christopher L; Korneluk, Robert G; Beug, Shawn T; LaCasse, Eric C; Bramson, Jonathan L.
Afiliación
  • Afsahi A; Centre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada.
  • Silvestri CM; McMaster Immunology Research Center, McMaster University, Hamilton, ON, Canada.
  • Moore AE; Department of Medicine, McMaster University, Hamilton, ON, Canada.
  • Graham CF; Centre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada.
  • Bacchiochi K; McMaster Immunology Research Center, McMaster University, Hamilton, ON, Canada.
  • St-Jean M; Department of Medicine, McMaster University, Hamilton, ON, Canada.
  • Baker CL; Centre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada.
  • Korneluk RG; McMaster Immunology Research Center, McMaster University, Hamilton, ON, Canada.
  • Beug ST; Department of Medicine, McMaster University, Hamilton, ON, Canada.
  • LaCasse EC; Centre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada.
  • Bramson JL; McMaster Immunology Research Center, McMaster University, Hamilton, ON, Canada.
Front Immunol ; 14: 1179827, 2023.
Article en En | MEDLINE | ID: mdl-37138866
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: FN-kappa B / Mieloma Múltiple Límite: Humans Idioma: En Revista: Front Immunol Año: 2023 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: FN-kappa B / Mieloma Múltiple Límite: Humans Idioma: En Revista: Front Immunol Año: 2023 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Suiza